India's Sun Pharmaceutical has received approval from the Australian Therapeutic Goods Administration (TGA) for its Winlevi (clascoterone) cream 1% for treating acne vulgaris in patients aged 12 and older. Winlevi's unique mechanism of action targets androgen receptors in the sebaceous glands and hair follicles, reducing sebum production and inflammation.
Sun Pharma's collaboration with Cosmo has granted it exclusive development and commercialization rights for Winlevi in several countries, including Australia. Winlevi's availability in Australia from June will provide physicians with an additional treatment option for acne.
The active ingredient in Winlevi, clascoterone, competes with androgens like dihydrotestosterone (DHT) for binding to androgen receptors. In acne vulgaris, elevated androgen levels contribute to increased sebum production and inflammation. Winlevi's ability to inhibit this process reduces sebum production and inflammation, leading to improved acne symptoms.
Sun Pharmaceutical, a global leader in specialty generics, offers a comprehensive portfolio of specialty, generic, and consumer healthcare products.